Form 4: Acrivon CEO & EVP Boost Stakes with Share Purchases

Acrivon Therapeutics' CEO and EVP of Business Operations, Peter Blume-Jensen and Kristina Masson, reported open market purchases of common stock.

Summary

• Peter Blume-Jensen, President and CEO of Acrivon Therapeutics, Inc., acquired 49,000 shares of the company's common stock.
• The transaction occurred on January 14, 2026, at a weighted average purchase price of $1.676 per share, with individual trades ranging from $1.66 to $1.68.
• Following this purchase, Dr. Blume-Jensen directly beneficially owns 2,095,771 shares of Acrivon Therapeutics common stock.
• Kristina Masson, EVP Business Operations and spouse of Dr. Blume-Jensen, indirectly beneficially owns 314,706 shares, for which Dr. Blume-Jensen disclaims beneficial ownership except to the extent of his pecuniary interest.
• Dr. Masson also disclaims beneficial ownership of the shares held by Dr. Blume-Jensen, except to the extent of her pecuniary interest therein.

Sentiment

Score: 7

Explanation: The insider purchases by both the CEO and EVP indicate a strong vote of confidence in the company's current valuation and future prospects, which is generally a positive signal for investors.

Positives

• Insider buying by the President and CEO, Peter Blume-Jensen, signals strong management confidence in the company's future prospects.
• The purchase by the EVP of Business Operations, Kristina Masson, further reinforces positive sentiment from key executives.
• The acquisition price of $1.676 per share suggests management believes the stock is undervalued at current levels.

Future Outlook

This filing does not contain any forward-looking statements or guidance.

Management Comments

• The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in footnote 1 of this Form 4.

Industry Context

Insider purchases in the biotechnology sector can sometimes indicate management's belief in upcoming clinical trial results or regulatory milestones, especially for a company like Acrivon Therapeutics, which is likely in the drug development phase. However, this filing alone does not provide specific context beyond the transaction itself.

Comparison to Industry Standards

• This Form 4 filing reports a standard insider transaction and does not provide data for comparison to industry-specific operational or financial benchmarks.
• Insider buying activity is generally viewed positively across all industries, signaling management confidence.

Related Party Transactions

• The filing notes that Dr. Peter Blume-Jensen and Dr. Kristina Masson are spouses, and each disclaims beneficial ownership of the shares held by the other except to the extent of their pecuniary interest. This clarifies the nature of their indirect holdings.

Stakeholder Impact

• Shareholders: May view the insider purchases as a positive signal of management confidence, potentially influencing investor sentiment and demand for the stock.

Key Dates

Recommendation

While insider buying by the CEO and EVP is a positive indicator of management's confidence in Acrivon Therapeutics, this Form 4 filing alone does not provide sufficient fundamental information (e.g., financial performance, pipeline updates, strategic developments) to warrant a 'buy' recommendation. It suggests a 'hold' for existing investors, as it reinforces a positive sentiment, but new investors would require more comprehensive due diligence beyond this transaction report.

Keywords

Acrivon Therapeutics, ACRV, Insider Trading, Stock Purchase, CEO, EVP, Peter Blume-Jensen, Kristina Masson, Form 4, Biotechnology, Pharmaceuticals